← Back to Clinical Trials
Recruiting NCT06081881

NCT06081881 Chronic Thromboembolic Pulmonary Hypertension After Pulmonary Embolism

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06081881
Status Recruiting
Phase
Sponsor Ester Ashraf Faried Beshay
Condition Chronic Thromboembolic Pulmonary Hypertension
Study Type OBSERVATIONAL
Enrollment 100 participants
Start Date 2025-01-01
Primary Completion 2026-10-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 80 Years
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 100 participants in total. It began in 2025-01-01 with a primary completion date of 2026-10-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

to detect the incidence of CTEPH patients. Primary outcome To predict CETHP in symptomatic patients after pulmonary embolism episode. Secondary outcome: On Echocardiography revealed RV dysfunction which are peak TR Velocity , the RV/LV basal diameter ratio, flattening of the IVS, RV acceleration time and/or midsystolic notching, IVC diameter with decreased inspiratory collapse and RA area.

Eligibility Criteria

Inclusion Criteria: Any patient diagnosed as acute pulmonary embolism ,aged between 18-80 years old which Pulmonary Embolism Severity Index (PESI) class III-V or sPESI ≥1, Exclusion Criteria: Secondary causes for pulmonary hypertension Severe kidney injury(eGFR\>30 mg/dl/1.7m2) Hepatic affection Contraindication to anti-coagulation

Contact & Investigator

Central Contact

Ester A Faried, resident

✉ esterashraf1810@gmail.com

📞 01277194352

Principal Investigator

Ester A Faried, Resident

PRINCIPAL INVESTIGATOR

Assiut University

Frequently Asked Questions

Who can join the NCT06081881 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Chronic Thromboembolic Pulmonary Hypertension. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06081881 currently recruiting?

Yes, NCT06081881 is actively recruiting participants. Contact the research team at esterashraf1810@gmail.com for enrollment information.

Where is the NCT06081881 trial being conducted?

This trial is being conducted at Asyut, Egypt.

Who is sponsoring the NCT06081881 clinical trial?

NCT06081881 is sponsored by Ester Ashraf Faried Beshay. The principal investigator is Ester A Faried, Resident at Assiut University. The trial plans to enroll 100 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology